8-K: GT Biopharma Faces Nasdaq Delisting Warning

GT Biopharma, Inc. received a notice from Nasdaq regarding non-compliance with the $1 minimum bid price requirement, initiating a 180-day compliance period.

Summary

• GT Biopharma, Inc. (GTBP) received a letter from Nasdaq on November 20, 2025, notifying it of non-compliance with the $1 minimum bid price requirement.
• The company's common stock closed below $1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• GT Biopharma has a compliance period of 180 calendar days, until May 19, 2026, to regain compliance.
• To regain compliance, the common stock's closing bid price must be at least $1.00 for a minimum of ten consecutive business days.
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market.
• The company intends to monitor its stock price and evaluate options to meet the requirement.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event with the Nasdaq delisting notice due to sustained low stock price. While a compliance period is granted, the risk of delisting is high, and there is no assurance of regaining compliance. This suggests a very challenging outlook for the company's market standing.

Positives

• The notice has no immediate effect on the listing of the company's common stock, which will continue to trade on The Nasdaq Capital Market under the symbol GTBP.
• The company has a 180-day compliance period to regain compliance, offering a window to address the issue.
• There is a possibility of an additional 180-day compliance period if certain conditions are met, including potentially effecting a reverse stock split.

Negatives

• GT Biopharma's common stock has traded below $1 per share for 30 consecutive business days, indicating sustained low market valuation.
• The company is not in compliance with Nasdaq's minimum bid price requirement, posing a significant risk to its continued listing.
• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement.

Risks

• Delisting from Nasdaq: If the company fails to regain compliance with the $1 minimum bid price requirement within the allotted period, its stock will be subject to delisting from The Nasdaq Capital Market.
• Inability to Regain Compliance: There is no assurance that the company will be able to achieve a closing bid price of at least $1.00 for ten consecutive business days.
• Failure to Meet Other Listing Rules: The company may also fail to comply with other applicable Nasdaq listing rules, which could lead to delisting.
• Market Perception: Continued trading below $1 and the delisting notice can negatively impact investor confidence and market perception.

Future Outlook

The company intends to monitor the closing bid price of its common stock and assess available options to regain compliance with the Minimum Bid Price requirement and continue listing on The Nasdaq Capital Market. However, there is no assurance that compliance will be regained.

Management Comments

• "The Company intends to monitor the closing bid price of the Common Stock and assess its available options to regain compliance with the Minimum Bid Price requirement and continue listing on The Nasdaq Capital Market."
• "There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price requirement or will otherwise be in compliance with other applicable Nasdaq listing rules."

Industry Context

This announcement highlights the ongoing challenge for smaller biotechnology companies to maintain compliance with exchange listing standards, particularly the minimum bid price rule, which can be indicative of market confidence and operational stability. Companies in the biotech sector often face volatility and can experience periods of low stock prices due to clinical trial results, funding needs, or market sentiment, making adherence to such rules critical for maintaining investor visibility and access to capital markets.

Comparison to Industry Standards

• Many small-cap biotechnology companies listed on Nasdaq face similar challenges in maintaining the $1 minimum bid price, especially those in early development stages without significant revenue.
• Companies like Sorrento Therapeutics (SRNEQ) and Athersys (ATHX) have previously faced Nasdaq delisting notices due to bid price deficiencies, often leading to reverse stock splits or eventual delisting if compliance is not achieved.
• The 180-day compliance period and potential for an additional 180-day extension are standard procedures for Nasdaq-listed companies facing this specific non-compliance issue.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced liquidity, lower stock price, and potential transfer to over-the-counter markets, making shares harder to trade.
• Investors: May lose confidence due to the non-compliance and delisting risk, potentially leading to further sell-offs.
• Company Management: Must dedicate resources and strategic focus to addressing the compliance issue, potentially diverting attention from core business operations.

Next Steps

• Monitor the closing bid price of the common stock.
• Assess available options to regain compliance with the Minimum Bid Price requirement.
• Potentially effect a reverse stock split if necessary to cure the deficiency, especially if seeking an additional compliance period.

Key Dates

Recommendation

The company faces a significant risk of delisting from Nasdaq due to its failure to maintain the minimum bid price. While a compliance period is granted, there is no assurance of regaining compliance, and the need for a potential reverse stock split indicates a fundamental issue with the stock's valuation. Delisting would severely impact liquidity and investor confidence, making the stock a high-risk investment with substantial downside potential. Investors should consider selling to avoid further potential losses and the complications associated with an OTC-traded stock.

Keywords

GT Biopharma, GTBP, Nasdaq, delisting, minimum bid price, compliance, biopharma, stock market, SEC filing, 8-K